KIT与PDGFRA突变对接受辅助伊马替尼治疗的胃肠间质瘤患者生存的影响:一项随机临床试验的探索性分析
基于SSGXVIII/AIO多中心随机试验的探索性分析,纳入341例接受手术及辅助伊马替尼1年或3年治疗的高危胃肠间质瘤患者,中位随访88个月。KIT外显子11缺失/插入缺失突变患者从3年治疗中获益最大(5年无复发生存率71.0% vs 41.3%,P<.001),其他突变亚组未见显著获益。
要点
- KIT外显子11缺失/插入缺失突变患者接受3年辅助伊马替尼的5年无复发生存率优于1年(71.0% vs 41.3%,P<.001)。
- PDGFRA突变及KIT外显子11插入或重复突变与较好无复发生存相关,KIT外显子9突变与不良结局相关。
- 其他突变亚组未观察到3年治疗较1年治疗的显著获益。
核心结论
- KIT外显子11缺失突变患者从更长疗程的辅助伊马替尼中获益最大。
- 辅助伊马替尼疗程可改变某些KIT突变(包括影响外显子11密码子557和/或558的缺失)相关的胃肠间质瘤复发风险。
研究设计与样本
- 基于Scandinavian Sarcoma Group VIII/Arbeitsgemeinschaft Internistische Onkologie(SSGXVIII/AIO)多中心随机临床试验的探索性分析。
- 2004年2月4日至2008年9月29日,400例高危胃肠间质瘤术后患者随机接受辅助伊马替尼1年或3年治疗。
- 397例提供知情同意,其中341例(85.9%)经中心确认的局限性胃肠间质瘤并采用常规测序进行中心KIT和PDGFRA突变分析。
- 中位随访88个月(截至2013年12月31日),142例患者出现胃肠间质瘤复发。
- 可评估人群数据分析时间为2004年2月4日至2013年12月31日。
主要发现
- 341例患者中,274例(80.4%)为KIT突变,43例(12.6%)为PDGFRA突变,24例(7.0%)为野生型。
- PDGFRA突变和KIT外显子11插入或重复突变与较好无复发生存相关,KIT外显子9突变与不良结局相关。
- KIT外显子11缺失或插入缺失突变患者中,3年组5年无复发生存率为71.0%,1年组为41.3%(P<.001)。
- 其他突变亚组中未发现3年治疗较1年治疗的显著获益。
- KIT外显子11缺失突变、涉及密码子557和/或558的缺失以及导致pTrp557_Lys558del的缺失,在1年组与不良无复发生存相关,但在3年组未观察到该关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Little is known about whether the duration of adjuvant imatinib influences the prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor α (PDGFRA) mutations. OBJECTIVE: To investigate the effect of KIT and PDGFRA mutations on recurrence-free survival (RFS) in patients with gastrointestinal stromal tumors (GISTs) treated with surgery and adjuvant imatinib. DESIGN, SETTING, AND PARTICIPANTS: This exploratory study is based on the Scandinavian Sarcoma Group VIII/Arbeitsgemeinschaft Internistische Onkologie (SSGXVIII/AIO) multicenter clinical trial. Between February 4, 2004, and September 29, 2008, 400 patients who had undergone surgery for GISTs with a high risk of recurrence were randomized to receive adjuvant imatinib for 1 or 3 years. Of the 397 patients who provided consent, 341 (85.9%) had centrally confirmed, localized GISTs with mutation analysis for KIT and PDGFRA performed centrally using conventional sequencing. During a median follow-up of 88 months (completed December 31, 2013), 142 patients had GIST recurrence. Data of the evaluable population were analyzed February 4, 2004, through December 31, 2013. MAIN OUTCOMES AND MEASURES: The main outcome was RFS. Mutations were grouped by the gene and exon. KIT exon 11 mutations were further grouped as deletion or insertion-deletion mutations, substitution mutations, insertion or duplication mutations, and mutations that involved codons 557 and/or 558. RESULTS: Of the 341 patients (175 men and 166 women; median age at study entry, 62 years) in the 1-year group and 60 years in the 3-year group), 274 (80.4%) had GISTs with a KIT mutation, 43 (12.6%) had GISTs that harbored a PDGFRA mutation, and 24 (7.0%) had GISTs that were wild type for these genes. PDGFRA mutations and KIT exon 11 insertion or duplication mutations were associated with favorable RFS, whereas KIT exon 9 mutations were associated with unfavorable outcome. Patients with KIT exon 11 deletion or insertion-deletion mutation had better RFS when allocated to the 3-year group compared with the 1-year group (5-year RFS, 71.0% vs 41.3%; P < .001), whereas no significant benefit from the 3-year treatment was found in the other mutational subgroups examined. KIT exon 11 deletion mutations, deletions that involved codons 557 and/or 558, and deletions that led to pTrp557_Lys558del were associated with poor RFS in the 1-year group but not in the 3-year group. Similarly, in the subset with KIT exon 11 deletion mutations, higher-than-the-median mitotic counts were associated with unfavorable RFS in the 1-year group but not in the 3-year group. CONCLUSIONS AND RELEVANCE: Patients with KIT exon 11 deletion mutations benefit most from the longer duration of adjuvant imatinib. The duration of adjuvant imatinib modifies the risk of GIST recurrence associated with some KIT mutations, including deletions that affect exon 11 codons 557 and/or 558. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116935.
引用
- Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 28334365. doi:10.1001/jamaoncol.2016.5751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。